GKGerman V. Kukushkin

German V. Kukushkin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


German V. Kukushkin has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Antidepressants and older age: risks of pharmacotherapy

    by German V. Kukushkin, Dmitry E. Yurov, Elena V. Kalinina, Ekaterina E. Burenkova, Daniil A. Devushkin, Юров Дмитрий Евгеньевич

    High prevalence of depression among older adults is a significant global public health concern. The situation is further aggravated by population aging, which increases the number of individuals requiring care. Alongside with psychotherapy, pharmacotherapy is widely used in depression management. However, its use in older adults poses substantial challenges due to age-related physiological changes and an elevated risk of adverse drug reactions. Multimorbidity and associated polypharmacy further contribute to the likelihood of harmful drug-drug interactions. In addition, aging-related changes affect drug elimination. Various classes of antidepressants with generally comparable efficacy are available on the pharmaceutical market. Tricyclic antidepressants, such as amitriptyline and imipramine, are not recommended in older adults due to a high incidence of adverse effects, including sedation, dry mouth, constipation, and orthostatic hypotension. Serotonin reuptake inhibitors, such as fluoxetine, sertraline, and citalopram, have a more favorable safety profile and are considered first-line agents in the treatment of depression in the elderly, although they are not without drawbacks. Selective serotonin and norepinephrine reuptake inhibitors, such as venlafaxine and duloxetine, act on two neurotransmitter systems, which may increase the likelihood of adverse effects. Atypical antidepressants (mirtazapine, trazodone, vortioxetine, and agomelatine) constitute a heterogeneous group of agents that differ in their mechanisms of action and safety profiles. Thus, when treating older adults, the rational choice of an antidepressant should consider its side effect profile, potential drug interactions, comorbid conditions, and cost of therapy.

  • Open Access

    Effect of drugs of various groups on the pharmacokinetics of cefotaxime in comparison with their effect on lymphatic tissue drainage

    by G. V. Kukushkin, L. P. Sviridkina

    Introduction. The lymphatic system plays a key role in spreading pathogens, including those causing intraabdominal infections. An urgent task of pharmacology is to create methods for the targeted delivery of antibiotics to lymphatic vessels and intestinal tissues. One approach is to use agents acting as endolymphatic conductors to achieve a high drug concentration in the lymphatic system. Aim. To evaluate the effect of various drugs on the concentration of cefotaxime, a third-generation antibiotic, in blood and intestinal tissues, as well as on lymphatic drainage in experiments on mice. Materials and methods. We investigated the effect of hyaluronidase (HLRD), bovgialuronidase azoximer (BovGLRD+Az), terrilitin (TRL), papaya milky juice (PMJ ), sodium heparin (HepS ), aprotinin (APRT), azoximer bromide (AzBrom), furosemide (FRSD) and sodium deoxyribonucleate (DRN) on the removal time of lymphotropic dye from mouse mesentery and the cefotaxime concentration in blood plasma and intestinal tissues by high-performance liquid chromatography. Results. HLRD reduced the time of dye removal from the mesentery by 26.2%, BovGLRD+Az – by 33.5%, TRL – by 36%, PMS – by 23.1%, HepS – by 30.1%, APRT – by 34.6%. The differences in lymphostimulating activity between these drugs were not statistically significant. AzBrom and FRSD increased the dye removal time by 8.3% and 6%, respectively; the DRN had no effect. HLRD, BovGLRD, TRL, PMJ, HepS and APRT increased the CF concentration in blood and intestinal tissues 1.5 and 24 hours after injection, in contrast to the single injection of antibiotic. AzBrom increased the CF concentration only after 1.5 hours. FRSD increased the antibiotic concentration in intestinal tissues but not in blood plasma. The DRN did not affect the studied indicators. Conclusion. Lymphostimulating drugs HLRD, BovGLRD, TRL, PMJ, HepS and APRT effectively direct the antibiotic to the lymphatic system and can be used for lymphotropic therapy.

  • THE POSSIBILITIES OF USING PROTEOLYTIC ENZYMES IN LYMPHOTROPIC THERAPY

    by Kukushkin G.V., Zhuravleva M.V., Yurov D.E.

    Proteolytic enzymes have a variety of pharmacological effects, which determines their important role and place in clinical medicine. The aim of this study was to confirm the lymphostimulating effect of terrilytin, an integral part of the drug terridecase, and to study its effect on the pharmacokinetic parameters of cefotaxime. Materials and methods of research. Assessment of the rate of lymphatic drainage in the mesentery of mice by the time of removal of lymphotropic dye from it; determination of the concentration of the antibiotic cephalosporin antibiotic of the third generation cefotaxime in rabbit blood plasma during the day, blood plasma, intestinal tissues and liver of white mongrel mice after 1.5 and 24 hours of experiment by high-performance liquid chromatography. Results. It has been confirmed that terrilytin has a lymphostimulating effect. It has been established that this proteolytic enzyme has the properties of an endolymphatic conductor. Its preliminary administration increases the concentration of cefotaxime in the blood plasma of rabbits and mice compared with monovision of the antibiotic at all time points of the study, up to a day, and increases its content in the intestinal tissue of mice, both 1.5 hours and 24 hours after injection of drugs. Terrilytin does not affect the level of cefotaxime in the liver tissue of mice, but reduces the ratio of its concentrations "liver tissue/blood", which indirectly indicates a decrease in liver extraction of the antibiotic. Conclusion. Terrilytin in clinical practice was used topically (externally or electrophoretically), whereas our studies were conducted against the background of its parenteral administration. This obstacle can be overcome by using a polyglucine–modified form of terrilytin – terridecase, which is allowed for parenteral administration. In this regard, it is advisable to continue studying the combined drug terridecase in order to identify its ability to direct water-soluble antibiotics into the lymphatic system.

  • Open Access

    Influence of drugs with hyaluronidase activity on the survival of animals with a purulent-inflammatory process in the abdominal organs

    by German V. Kukushkin, Marina V. Zhuravleva, Dmitry E. Yurov, Юров Дмитрий Евгеньевич

    BACKGROUND: The optimization of the pharmacokinetics of antibiotics is an important aspect in improving the effectiveness of therapy for intra-abdominal infections. Thus, studying the survival of experimental animals with a simulated purulent-inflammatory process in abdominal organs using the combined use of antibacterial agents with endolymphatic agents is worthwhile. AIMS: To examine the effect of the co-administration of cefotaxime and hyaluronidase or bovgyaluronidase azoximer on the survival of mice with a purulent-inflammatory process of the abdominal organs. MATERIALS AND METHODS: The purulent-inflammatory process of the abdominal organs, which was simulated by the intraperitoneal administration of a lethal dose of Staphylococcus aureus microbial suspension to mice, was evaluated. Four study groups were formed, with 28 animals each. Group 1 did not receive treatment, group 2 was administered with cefotaxime, and groups 3 and 4 received antibiotics after preliminary administration of hyaluronidase or bovgialuronidase azoximer. For the statistical analysis of animal survival, the Kaplan–Meier multiple assessment method was used, and a univariate analysis using a log-rank test was employed to identify significant differences between the groups. RESULTS: During the study, a single injection of cefotaxime alone and in combination with other studied drugs promoted the survival of some mice with a simulated purulent-inflammatory process of the abdominal organs compared with the untreated group, and at the end of the experiment (day 7), 100% of the animals died. Moreover, the best results were achieved with the initial administration of hyaluronidase or bovhyaluronidase azoximer. Thus, on day 7 of observation, 70% of the animals in groups that received both an antibiotic and hyaluronidase or bovgyaluronidase azoximer survived. No statistically significant differences were found in the effect of these drugs on animal survival in the presence of an experimental purulent-inflammatory process. CONCLUSION: A single injection of cefotaxime alone or in combination with other studied drugs ensures the survival of some mice with a simulated purulent-inflammatory process of the abdominal cavity compared with the control group, in which 100% of the animals died by the end of the experiment (day 7). Moreover, the best results were achieved in groups initially administered with hyaluronidase or bovgialuronidase azoximer.

  • Open Access

    Ademetionine treatment cost analysis of patients with intrahepatic cholestasis and non-alcoholic fatty disease

    by M. V. Zhuravleva, G. V. Kukushkin, E. V. Luchinina, T. V. Shelekhova, T. R. Kameneva, E. V. Kuznetsova, E. A. Luchinin

    Анализ стоимости лечения адеметионином больных внутрипечёночным холестазом и неалкогольной жировой болезнью печени


  • Antibiotic treatment failure

    by Sergey P. Alpatov, Nadezhda V. Bogush, Denis A. Borozdenko, Natalia M. Buyanova, Irina V. Ganshina, Gulnara O. Dibirova, Natalia B. Dmitrieva, Elena V. Kalinina, Anna V. Kirillova, Nina M. Kiseleva, et al.

    This review presents information on cases of antibiotic failure (insufficient effect) in the global population over the past three years. We analyzed scientific papers, clinical trial data, and the WHO Program for International Drug Monitoring (VigiBase) data from 2018 to 2020. The values of global success and safety rates of antibacterial drugs for medical use are presented. The findings may be of practical interest to physicians, researchers, developers, and healthcare regulators.

  • Vaccine safety for COVID-19 prevention

    by Boris K. Romanov, Sergey P. Alpatov, Nadezhda V. Bogush, Denis A. Borozdenko, Natalia M. Buyanova, Irina V. Ganshina, Gulnara O. Dibirova, Natalia B. Dmitrieva, Elena V. Kalinina, Anna V. Kirillova, et al.

    BACKGROUND: In 2021, the Uppsala Monitoring Center of the World Health Organization included 52 vaccines for coronavirus disease-2019 (COVID-19) prevention in the international database, VigiBase, and almost immediately, this group of medicines (drugs) took the lead in the increased rate of reported adverse reactions (ARs). AIM: This study aimed to review the case reports of ARs from COVID-19 vaccines in the VigiBase database. MATERIALS AND METHODS: Statistical analysis of cases that describe ARs in the international pharmacovigilance VigiBase database was performed. RESULTS: On May 12, 2021, the VigiBase database included 26,099,906 reports that describe AR cases on drugs, including 585,744 reports of AR on vaccines for COVID-19 prevention. Serious ARs after immunization with these vaccines were registered in 31.5% of reports, including 0.9% fatal and 1.3% life-threatening. Headache (37.1% of reports), pyrexia (31.1%), chills (23.2%), and fatigue (22.7%) were most frequently recorded. CONCLUSIONS: More data are required to confirm the association between the COVID-19 vaccines and the increased risk of ARs following their use.

  • Open Access

    Drug Safety for Children — International Monitoring Data for 50 Years

    by B. K. Romanov, Yu. V. Olefir, R. N. Alyautdin, S. V. Glagolev, V. A. Polivanov, L. I. Ilienko, S. P. Alpatov, N. V. Bogush, N. M. Buyanova, I. V. Ganshina, et al.

    Безопасность применения лекарственных средств у детей — данные международного мониторинга за 50 лет